Non-irritating testosterone emulsions
Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.
1. A method of treating meibomian gland disease, the method comprising topical ocular administration of an emulsion composition, the composition comprising testosterone at a concentration of about 0.1% (w/w) or 0.3% (w/w); Castor oil at a concentration between about 0.10% (w/w) and about 5% (w/w); a cyclodextrin at a concentration between about 0.25% (w/w) and about 10% (w/w); a C10-30 alkyl acrylate crosspolymer at a concentration between about 0.01% (w/w) and about 5% (w/w); and Polyoxyl 40 stearate at a concentration between about 0.01% (w/w) and about 5% (w/w).
2. The method of claim 1 , wherein the castor oil is present in the composition at a concentration of between about 0.10% (w/w) and about 1% (w/w).
3. The method of claim 2 , wherein the castor oil is present in the composition at a concentration of between about 0.10% (w/w) and about 0.5% (w/w).
4. The method of claim 3 , wherein the castor oil is present in the composition at a concentration of about 0.25% (w/w).
5. The method of claim 4 , wherein the cyclodextrin is sulfobutyl ether-β-cyclodextrin present in the composition at a concentration of between about 0.25% (w/w) and about 5% (w/w).
6. The method of claim 5 , wherein the sulfobutyl ether-β-cyclodextrin is present in the composition at a concentration of between about 0.25% (w/w) and about 5% (w/w).
7. The method of claim 6 , wherein the sulfobutyl ether-β-cyclodextrin is present in the composition at a concentration of about 0.36% (w/w), 1.25% (w/w), or about 3.75% (w/w).
8. The method of claim 7 , wherein the C10-30 alkyl acrylate crosspolymer is present in the composition at a concentration of between about 0.01% (w/w) and about 1% (w/w).
9. The method of claim 8 , wherein the C10-30 alkyl acrylate crosspolymer is present in the composition at a concentration of about 0.1% (w/w).
10. The method of claim 9 , wherein the Polyoxyl 40 stearate is present in the composition at a concentration of between about 0.01% (w/w) and about 2% (w/w).
11. The method of claim 10 , wherein the Polyoxyl 40 stearate is present in the composition at a concentration of between about 0.01% (w/w) and about 1% (w/w).
12. The method of claim 11 , wherein the Polyoxyl 40 stearate is present in the composition at a concentration of about 0.25% (w/w).
13. The method of claim 12 , wherein the composition further comprises Polysorbate 80 at a concentration of between about 0.01% (w/w) and about 5% (w/w).
14. The method of claim 13 , wherein the Polysorbate 80 is present in the composition at a concentration of between about 0.01% (w/w) and about 1% (w/w).
15. The method of claim 14 , wherein the Polysorbate 80 is present in the composition at a concentration of about 0.25% (w/w).
16. The method of claim 15 , wherein the composition further comprises glycerin at a concentration of between about 0.1% (w/w) and about 10% (w/w).
17. The method of claim 16 , wherein the glycerin is present in the composition at a concentration of between about 0.1% (w/w) and about 5% (w/w).
18. The method of claim 16 , wherein the glycerin is at a concentration of about 1.0% (w/w) or 1.5% (w/w).
19. The method of claim 18 , wherein the composition further comprises boric acid.
20. The method of claim 19 , wherein the composition further comprises sodium hydroxide.
21. The method of claim 20 , wherein the composition further comprises water.
22. The method of claim 1 , wherein the testosterone is present in the composition in a concentration of about 0.1% (w/w).
23. The method of claim 1 , wherein the testosterone is present in the composition in a concentration of about 0.3% (w/w).